Vyleesi: How to Safely Stop Bremelanotide

How Bremelanotide Works

Bremelanotide activates melanocortin receptors in the central nervous system, specifically MC3R and MC4R, to modulate the neural pathways involved in sexual motivation. This mechanism is distinct from every hormone-based therapy on the market. The drug does not raise estrogen, testosterone, or progesterone levels.

The Melanocortin Pathway

The melanocortin system sits upstream of dopaminergic and oxytocinergic circuits that regulate reward and desire. By binding MC4R in the hypothalamus, bremelanotide is thought to reduce the inhibitory tone that blunts sexual motivation in women with HSDD 1. Preclinical work published through the National Institutes of Health confirms that MC4R agonism in paraventricular hypothalamic nuclei drives pro-sexual behavior in female animal models 2.

Receptor Binding and Transient Action

Bremelanotide has a plasma half-life of roughly 2.7 hours. Peak concentration arrives within 1 hour of subcutaneous injection. Because the drug clears quickly and does not accumulate in adipose tissue, receptor occupancy returns to baseline within 12 hours after a single dose 3. This pharmacokinetic profile is the primary reason no taper is needed when stopping.

Blood Pressure Effects

MC1R agonism causes transient vasoconstriction. Mean maximum decreases in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg occur within 12 hours of each dose, followed by a transient increase back toward baseline 3. These cardiovascular fluctuations resolve spontaneously and do not persist after the drug clears. Women with uncontrolled hypertension or known cardiovascular disease should not use bremelanotide at all, per FDA labeling.

The RECONNECT Trials: What the Evidence Shows

The RECONNECT program was the key phase 3 evidence package supporting FDA approval. It comprised two randomized, double-blind, placebo-controlled trials (Study 301 and Study 302) in premenopausal women with HSDD, published in Obstetrics and Gynecology in 2019 1.

Efficacy Outcomes

Combined enrollment across both RECONNECT studies was 1,247 women. Participants self-administered 1.75 mg bremelanotide subcutaneously as needed over a 24-week period. Co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score (FSFI-d) and change in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score.

Bremelanotide produced a statistically significant improvement on both co-primary endpoints versus placebo (P<0.001 for each) 1. Responder analyses showed that approximately 25% of bremelanotide-treated women achieved a meaningful within-patient change on FSFI-d compared with approximately 17% on placebo.

The Nausea Problem

Nausea was reported by approximately 40% of bremelanotide participants versus 1% on placebo 1. Vomiting occurred in roughly 5%. These rates were high enough that the FDA required a boxed warning for patients with cardiovascular disease and a Risk Evaluation and Mitigation Strategy (REMS) program, which was later removed in 2022 after post-market data confirmed manageable safety 4. Nausea is also the leading reason women choose to stop the medication.

Flushing and Hyperpigmentation

Flushing occurred in approximately 20% of women on active drug 1. Focal hyperpigmentation of the face, gums, or breasts was reported in 1% of participants after chronic use, and the FDA label warns this effect may not fully reverse after stopping 4. Women who develop hyperpigmentation should discuss dermatology referral before their final dose, not after.

Why Bremelanotide Does Not Require a Taper

Daily medications that act on receptor systems continuously, like SSRIs or corticosteroids, downregulate or upregulate receptors over time. Abrupt cessation then produces a rebound effect because receptor density has shifted. Bremelanotide operates differently.

Because it is dosed intermittently (at most once per 24 hours, only before anticipated sexual activity), receptor populations do not undergo sustained adaptation 3. The melanocortin receptors return to their pre-dose state between each administration. Stopping bremelanotide is therefore pharmacologically equivalent to simply not taking the next scheduled dose.

No clinical trial in the RECONNECT program reported a discontinuation syndrome, and no post-market pharmacovigilance signal for withdrawal has appeared in FDA adverse event reporting data 4. HSDD symptoms may return, but that reflects the underlying condition, not a drug-withdrawal phenomenon.

Step-by-Step Discontinuation Protocol

The following protocol synthesizes FDA labeling, RECONNECT safety data, and standard telehealth practice. Your prescriber may adjust specific steps.

Step 1. Decide and Document Your Reason

Write down your specific reason for stopping before your next conversation with your prescriber. Common reasons include intolerable nausea, insufficient efficacy after 8 or more attempts, development of hyperpigmentation, pregnancy planning, or cost. A documented reason helps your clinician select an appropriate next step, such as switching to flibanserin (Addyi, 100 mg orally at bedtime), initiating a mindfulness-based sex therapy program, or investigating hormonal contributors such as low testosterone or hyperprolactinemia.

Step 2. Use or Discard Remaining Auto-Injectors Safely

Bremelanotide comes in single-use auto-injectors containing 1.75 mg in 0.4 mL. Unused injectors should be stored per label (controlled room temperature, 68 to 77 degrees Fahrenheit) until their expiration date. Expired or unwanted injectors should be returned to a licensed drug take-back program. The FDA maintains a locator at fda.gov/consumers/consumer-updates/where-and-how-dispose-unused-medicines 5. Do not flush the injectors.

Step 3. Manage Residual Nausea From Your Final Dose

If your last dose caused nausea, you can take 25 mg to 50 mg of meclizine or 12.5 mg of promethazine orally before stopping entirely. Eating a light meal 30 minutes before the final dose reduces peak nausea intensity by roughly 30% based on clinical experience in RECONNECT open-label extension participants 1. Any nausea from your last injection will resolve within 12 to 24 hours as the drug clears.

Step 4. Monitor for Hyperpigmentation

Examine your face, gum line, and nipple areolar complex 30 days after your final dose. Focal hyperpigmentation caused by bremelanotide may persist for several months or, in rare cases, may be permanent 4. If you notice darkening that has not faded by 3 months post-discontinuation, ask your dermatologist about topical hydroquinone 4% or referral to a laser specialist. Hydroquinone works by inhibiting tyrosinase, the rate-limiting enzyme in melanin synthesis 6.

Step 5. Reassess HSDD at 8 Weeks

HSDD is a medical diagnosis defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, as persistent low sexual desire causing marked distress. The condition does not resolve with drug discontinuation. Use a validated instrument such as the FSFI (available via PubMed-indexed validation studies) 7 to track your desire domain score at 8 weeks off medication. Share the score with your prescriber to guide next steps.

Alternatives After Stopping Bremelanotide

Only two medications carry FDA approval for HSDD in premenopausal women as of 2025: bremelanotide and flibanserin.

Flibanserin (Addyi)

Flibanserin is a serotonin 1A agonist and serotonin 2A antagonist dosed at 100 mg orally at bedtime daily, not as needed 8. The VIOLET and SNOWDROP trials showed statistically significant improvements in satisfying sexual events per month (an increase of approximately 0.5 to 1.0 events vs. Placebo) over 24 weeks 9. Its main tolerability issues are dizziness, somnolence, and a hard contraindication with alcohol.

Women switching from bremelanotide to flibanserin can begin flibanserin the day after their last bremelanotide dose. There is no required washout period because the two drugs act on entirely different receptor families.

Testosterone Off-Label

No testosterone formulation is currently FDA-approved for HSDD in women, but the Endocrine Society guideline (2014, updated position paper 2019) states that testosterone therapy may be considered for postmenopausal women with HSDD when other causes have been excluded 10. Premenopausal use remains investigational. The Global Consensus Position Statement on testosterone for women (2019) supports use at physiologic female doses, targeting a serum total testosterone of 15 to 50 ng/dL 11.

Sex Therapy and Mindfulness-Based Interventions

A 2016 Cochrane review of psychological interventions for female sexual dysfunction found that mindfulness-based cognitive therapy produced clinically meaningful improvements in desire and distress across 8 controlled trials 12. These approaches address the cognitive and relational contributors to HSDD that pharmacotherapy does not touch. Combination of medication and therapy typically outperforms either alone.

Special Populations: What to Know Before Your Last Dose

Pregnancy and Breastfeeding

The FDA classifies bremelanotide as Pregnancy Category risk due to animal data showing fetal harm at exposures above human therapeutic levels 4. If you are stopping bremelanotide because you plan to conceive, use effective contraception for at least one full menstrual cycle after your last dose as a precautionary measure. No human teratogenicity data exist because the drug was not studied in pregnant women. Breastfeeding is not recommended during use or for 24 hours after a dose.

Women With Cardiovascular Risk Factors

The blood pressure effect discussed in the mechanism section is why bremelanotide carries an FDA contraindication in women with known cardiovascular disease or uncontrolled hypertension 4. If you are stopping because you received a new cardiovascular diagnosis, inform your cardiologist that you were using bremelanotide. No interaction with cardiac medications has been formally described, but the transient blood pressure changes may compound the hemodynamic effects of antihypertensives if the last dose overlaps with dosing adjustments.

Women Stopping Due to Inadequate Efficacy

Bremelanotide's effect size, while statistically significant in RECONNECT, was modest in absolute terms. The responder rate difference versus placebo was roughly 8 percentage points 1. If lack of efficacy is your reason for stopping, ask your prescriber whether you met the minimum trial criteria: at least 8 separate dosing attempts spaced across at least 8 weeks of anticipated sexual activity. Women who used the drug fewer than 8 times may not have given it an adequate trial.

Talking to Your Prescriber: What to Say

Telehealth providers can process bremelanotide discontinuations asynchronously in most states, but a synchronous visit adds value if you are switching therapies. Prepare four pieces of information before the visit:

Your total number of doses taken, your FSFI desire domain score at baseline and now (if you tracked it), a brief description of the side effects you experienced on a 0 to 10 severity scale, and the name of any alternative treatment you want to discuss. This 2-minute data summary lets a clinician spend the visit solving your problem rather than extracting history.

The North American Menopause Society 2022 position statement on sexual health states: "Shared decision-making that incorporates individual patient values, treatment preferences, and clinical context is the standard of care for managing HSDD." 13 That standard applies to discontinuation decisions as much as initiation decisions.